Cangene and Barda extend botulism antitoxin contract

Posted: April 4, 2010 at 8:11 am

Story Summary: Cangene and Barda extend botulism antitoxin contract Readers are referred to the cautionary notes regarding Forward-looking information at the end of this release Listed TSX, Symbol: CNJ & , /CNW/ – Cangene Corporation today reports that it has signed a no-cost modification to extend its botulism antitoxin contract with the Biomedical Advanced Research and Development Authority (BARDA). BARDA is the department within the U. S. Department of Health and Human Services (HHS) that manages the two biodefence-related, stockpiling contracts Cangene has with HHS. This modified contract extends the product delivery schedule out to , with deliveries spread evenly over the next three contract years. Contracts of this nature are always somewhat fluid – we continue to have constructive discussions with BARDA regarding our existing contracts and potential new ones, said , Cangenes president and CEO. Botulinum toxin was specifically identified as a target for products developed under the U. S. Project BioShield. The Centers for Disease Control and Prevention recently announced that Cangenes product will be used in non-infant, public health situations under an Investigational New Drug protocol, replacing similar products that have expired. About Hyperimmunes Hyperimmunes are purified preparations of specific immune globulins isolated from blood plasma. Immune globulins are the class of proteins that function as antibodies. The Company has been manufacturing its WinRho(R) SDF hyperimmune product for nearly 30 years, which has established the manufacturing technology. Most recently, the Companys development efforts have been concentrated on developing products with infectious disease and bioterrorism targets. This risk also applies to unknown or emerging viruses and other pathogens. About Cangene Corporation Cangene is one of Canadas largest and earliest biopharmaceutical companies. Cangene has approximately 700 employees in eight locations across and its products are sold worldwide. It operates three large manufacturing facilities – two in , Manitoba and one in , Maryland – where it produces its own products and undertakes contract manufacturing for a number of companies. In addition, it has a regulatory affairs, sales and corporate communications office in , Ontario. Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. In addition, the Company has several more products in development at various stages. Cangene, WinRho and WinRho SDF are trademarks belonging to Cangene Corporation….Read the Full Story

Related posts:

  1. Cangene acquires U.S. commercialization rights for HepaGam B(R) from Apotex
  2. Cangenes Hepatitis B product approved by European Commission
  3. Cangene acquires Twinstrand Therapeutics Inc.

Related Post

Comments are closed.